Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
849.6 INR | -0.52% | +0.81% | +29.30% |
Jul. 11 | Glenmark Pharmaceuticals to Sell 7.84% Stake in Glenmark Life Sciences | MT |
Jul. 10 | Glenmark Pharma to Sell 7.84% Stake in Glenmark Life via Offer for Sale | CI |
Sales 2024 | 22.83B 273M | Sales 2025 * | 25.67B 307M | Capitalization | 105B 1.25B |
---|---|---|---|---|---|
Net income 2024 | 4.71B 56.34M | Net income 2025 * | 5.47B 65.41M | EV / Sales 2024 | 4.04 x |
Net cash position 2024 | 3.02B 36.09M | Net cash position 2025 * | 2.5B 29.94M | EV / Sales 2025 * | 3.98 x |
P/E ratio 2024 |
20.2
x | P/E ratio 2025 * |
19.1
x | Employees | 1,824 |
Yield 2024 |
2.9% | Yield 2025 * |
2.57% | Free-Float | 23.57% |
Latest transcript on Glenmark Life Sciences Limited
1 day | -1.08% | ||
1 week | +0.23% | ||
Current month | -2.84% | ||
1 month | -1.33% | ||
3 months | +5.72% | ||
6 months | +11.55% | ||
Current year | +28.56% |
Managers | Title | Age | Since |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 19-08-12 |
Director of Finance/CFO | - | 22-05-31 | |
Compliance Officer | - | 21-02-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 20-10-29 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 19-08-12 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 18-10-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-07-18 | 849.6 | -0.52% | 7 898 |
24-07-16 | 854 | +1.18% | 11,972 |
24-07-15 | 844.1 | -0.61% | 29,468 |
24-07-12 | 849.2 | +0.76% | 45,704 |
24-07-11 | 842.8 | -4.11% | 30,626 |
Delayed Quote Bombay S.E., July 18, 2024 at 02:15 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.35% | 815B | |
+31.64% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+15.51% | 247B | |
+16.72% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- GLS Stock
- GLS Stock